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Glucagon like peptide 1 (GLP-1) is an incretin hormone released as a bioactive peptide from intestinal L-cells in response to eating. It acts on
target cells and exerts several functions as stimulating insulin and inhibiting glucagon. It is quickly deactivated by the serine protease dipeptidyl
peptidase IV (DPP-IV) as an important regulatory mechanism. GLP-1 analogues are used as antidiabetic drugs in patients with type 2 diabetes.
We served patients with cystic ﬁbrosis (CF, n=29), cystic ﬁbrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized
breakfast (23 g protein, 25 g fat and 76 g carbohydrates) after an overnight fasting. Blood samples were collected before meal as well as 15, 30, 45
and 60 min after the meal in tubes preﬁlled with a DPP-IV inhibitor. The aim of the study was to compare levels of GLP-1 in patients with CF,
CFRD and in healthy controls.
We found that active GLP-1 was signiﬁcantly decreased in patients with CF and CFRD compared to in healthy controls (pb0.01). However,
levels in patients with CFRD tended to be lower but were not signiﬁcantly lower than in patients with CF without diabetes (p=0.06). Total GLP-1
did not differ between the groups, which points to that the inactive form of GLP-1 is more pronounced in CF patients. The endogenous insulin
production (measured by C-peptide) was signiﬁcantly lower in patients with CFRD as expected. However, levels in non-diabetic CF patients
did not differ from the controls.
We suggest that the decreased levels of GLP-1 could affect the progression toward CFRD and that more studies need to be performed in order
to evaluate a possible treatment with GLP-1 analogues in CF-patients.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis related diabetes (CFRD); GLP-1; Intestinal hormones; Endocrinology1. Introduction
The frequency of diabetes mellitus as a complication to
Cystic fibrosis (CF) is more than 30% in young adult individ-
uals and further increases with age. The prevalence will proba-
bly increase since the survival of CF patients is expected to
improve [1]. Cystic fibrosis related diabetes (CFRD) might be
due to the overall pancreatic insufficiency [2] and the ongoing⁎ Corresponding author. Biomedical Center, B11, Lund University, S214 84
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doi:10.1016/j.jcf.2011.11.001fibrosis in pancreatic tissue that destroys the islets of Langerhans
[3]. However, the correlation between insulin deficiency and
degree of fibrosis has not been found by all [4,5]. Insulin resis-
tance induced by chronic pulmonary infections has been pro-
posed as a possible contributor to the development of CFRD
[6] although this is also controversial [2]. Beta cell specific
pancreatic autoantibodies are not more frequent in CFRD com-
pared to the background population [7] and autoimmunity is
not generally considered to be the mechanism as in type 1 dia-
betes (T1D). However, one study noticed the presence of islet
cell antibodies in CF patients who were genetically predis-
posed with certain HLA-types with increased risk of develop-
ing autoimmune diabetes [8].by Elsevier B.V. All rights reserved.
Table 1
Contents of the meal.
Breakfast (Energy 617 kcal, protein 23 g, fat 25 g, carbohydrates 76 g)
50 g White wheat bread
50 g Dark whole meal bread
10 g Butter (80% fat)
30 g Cheese (28% fat)
40 g Orange marmalade
200 g Milk (3% fat)
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of the endoplasmic reticulum [9] but the process is not as rapid
as in T1D. Insulin therapy has been associated with an im-
provement of lung function and nutritional status in patients
with CFRD [10] and even in patients with CF with impaired
glucose tolerance (IGT) [11]. However, oral hypoglycemic
agents, normally effective for the treatment of type 2 diabetes
(T2D) have no proven effect in the treatment of CFRD [6]
although some data suggest a possible role for sulfonylurea [12].
Glucagon-like protein 1 (GLP-1) is a potent incretin hor-
mone released by intestinal L-cells in the distal ileum in re-
sponse to food intake [13]. It is released as a bioactive
peptide (7-36)amide or (7-37) with a half-life of just a few mi-
nutes due to rapid deactivation by dipeptidyl peptidase-IV
(DPP-IV), a functional amino peptidase in the CD26 complex
[14]. DPP-IV targets the N-terminal of peptides where the sec-
ond amino acid is alanine or proline. The N-terminal dipeptide
is cleaved off leaving a peptide without biologic function.
Bioactive GLP-1 interacts with the proper receptor on the tar-
get cells and exerts several effects. Among these, inhibition
of gastric emptying and gastric acid secretion [15-17] as well
as increased glucose-dependent insulin secretion from the
beta cells [18,19] are the best described. The glucose lowering
effect is further achieved as GLP-1 is also a potent inhibitor of
glucagon [19,20]. The insulinotropic action of the peptide has
made GLP-1 analogues and DPP-IV inhibitors useful as anti-
diabetic drugs [21-24].
The aim of this paper was to study levels of active and total
GLP-1 in response to a standardized mixed meal in patients
with CF and CFRD compared to in healthy controls.
2. Research design and methods
2.1. Subjects and sample collection
Subjects with CF (n=48) and healthy controls (n=18) were
recruited by invitation. The Center for Cystic Fibrosis at the
Department of Pulmonary Medicine at the Lund University
Hospital serves as one of four regional centra where patients
with CF are followed. All patients were adults but diagnosed
with CF during childhood.
Patients with CFRD (n=19) had a median age of 32 years,
range, 23–58 years, were diagnosed by a plasma gluco-
se≥11.0 mmol/L at a 2 h oral 75 g glucose tolerance test
(OGTT). A total of 12 men and 7 women were included with
CFRD.
Of the remaining 29 patients with CF, 26 had normal OGTT
with 2-h plasma glucose levels below 7.8 mmol/L and three
responded with impaired glucose tolerance (2-h plasma glucose
7.8–10.9 mmol/L). These three patients were referred to the
group of patients without diabetes in the further analyses. The
median age of this group was 28 years, range, 20–47 years. A
total of 16 men and 13 women were included with CF without
diabetes.
Healthy non-diabetic subjects (n=18) served as controls.
The median age was 33.5, range 23–60 years. A total of 7
men and 11 women were included as controls.2.2. Methods
All subjects were fasting overnight and a first blood sample
was drawn 5 min before serving breakfast (Table 1). Patients
with CFRD were instructed to not take insulin during overnight
fasting and did not have insulin before all blood samples were
collected after the meal. Blood samples were collected 15, 30,
45 and 60 min after the meal was finished in EDTA plasma
collection tubes (blood volume 7 mL) prepared with 100 μL
DPP-IV inhibitor (DPP4-010, Linco Research Inc, St. Charles,
MO, USA). The fasting sample (0 min) was drawn in two EDTA-
plasma tubes with and without the inhibitor. All samples were
immediately placed on ice, blood cells were removed by centrifu-
gation (2200×g) and the plasma was stored in −80 °C until
analysis.
Diabetes specific autoantibodies were analyzed to define any
autoimmune origin of diabetes in the patients with CF. Glutamic
acid decarboxylase 65 (GAD65) is the most prevalent islet specif-
ic antigen during autoimmune diabetes in adult subjects and was
analyzed by a radioimmunoprecipitating assay. Briefly, 35S-la-
beled in-vitro translated recombinant antigen was prepared
using a plasmid (pGAD65cDNAII) and TNT SP6 Coupled Re-
ticulocyte System Kit (L4600, Promega, USA) according to
manufacturer's instructions. Human EDTA-plasma (5 μL) with-
out the DPP-IV inhibitor incubated with 35S-labeled GAD65
overnight at +4 °C. GAD65 antibodies in plasma interact with
the 35S-labeled antigen and duplicates of 50 μL were precipitat-
ed on protein A sepharose (50 μL) on high affinity protein mem-
brane filter plates (MADVN6550, Molsheim, France) precoated
with 1% BSA. Several steps of washing discarded unbound an-
tigen and the 35S activity was measured (Packard Tri-carb
2100 TR, Meriden, CT, USA). The specificity of the assay was
100% and the sensitivity was 70% in the first diabetes antibody
standardization program [25]. The cut-off limit for positivity was
21.2 WHO units/mL.
C-peptide was analyzed with an ELISA (10-1136-01,
Mercodia, Uppsala, Sweden), with an assay range between
100 and 4000 pmol/L and a sensitivity of 15 pmol/L, to esti-
mate the insulin response. Total GLP-1 was analyzed with a
125I-radioimmunoassay (GLP1T-36HK, Linco Research, St
Charles, Mi, USA) with antibodies targeting the C-terminal.
Active GLP-1 was analyzed by fluorescence ELISA (EGLP-
35K, Linco Research, St Charles, Mi, USA) with antibodies
targeting the N-terminal. All steps were performed according
to manufacturer's instructions.
The study was approved by The Regional Ethical Board at
Lund University (43/2005).
Fig. 1. The lines show the median GLP-1 levels at different points of time after
ingestion of the meal. Panel A shows the level of total GLP-1 and panel B the
level of active GLP-1 in healthy control subjects ( ⃝ , n=18), in patients with
cystic fibrosis without the presence of diabetes (∎, n=29) and in patients with
cystic fibrosis related diabetes, CFRD (♦, n=19). Panel B, Area under the
curve (AUC) analysis showed significantly higher levels of active GLP-1 in
healthy subjects compared to in CFRD (p=0.001) as well as in CF patients
without diabetes (p=0.02).
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Kolmogorov–Smirnov test was applied to test for normal
distribution. The test is based on the maximum discrepancy
between the sample and normal cumulative distribution. Area
under the curve (AUC) was compared between the groups for
total and active GLP-1 as well as C-peptide. In addition, levels
were compared using independent samples T-test or Mann–
Whitney U-test where appropriate. All statistical data was ana-
lyzed in MedCalc® for Windows version 10.4.0.0. The α-value
was set to 5%.
3. Results
Levels of active GLP-1 was significantly lower in patients
with CFRD compared to the controls (AUC, p=0.001). AlsoTable 2
Active GLP-1 concentrations (pmol/L) in controls, patients with cystic fibrosis witho
are presented as median levels followed by interquartile range (IQR).
O min 15 min
Controls (n=18) 5.2 (3.1–8.4) 7.0 (4.1–9.5)
CF (n=29) 1.9 (1.0–3.9) 4.2 (3.5–5.8)
CFRD (n=19) 1.7 (1.1–2.9) 3.7 (2.7–5.3)the patients with CF without diabetes had significantly reduced
levels compared to the controls (AUC, p=0.02). The Mann–
Whitney U-test at every time point did also indicate a signifi-
cant difference.
When comparing GLP-1 levels in CF patients with or with-
out the presence of diabetes mellitus the active GLP-1 showed a
tendency to be further reduced in CFRD (Fig. 1, panel B;
Table 2), however, this was not statistically significant
(p=0.06). Levels of total GLP-1 (including the DPP-IV pro-
cessed peptide) did not differ at all between patients and con-
trols. Total GLP-1 was also similar in all subjects with CF
regardless of diabetic status (Table 3).
High titers of autoantibodies against glutamic acid decar-
boxylase 65 (GAD65) was found in a 25 year old woman with
CF and with clinical onset of diabetes at the age of 20 years.
Her fasting C-peptide was within normal range (0.47nM) and
she was clinically classified as having CFRD and not T1D.
None of the other patients or controls included were considered
positive for GAD65 or IA-2 autoantibodies.
The C-peptide was significantly reduced in patients with
CFRD compared to non-diabetic subjects with CF (AUC,
p=0.0001) and controls (AUC, p=0.0001). However, C-
peptide did not differ between controls and CF patients without
diabetes (AUC, p=0.98) (Fig. 2, Table 4).
4. Discussion
In this study we found that patients with CF had signifi-
cantly lower levels of active GLP-1 (7–37 and 7-36amide)
(pb0.01) compared to in controls (Fig. 1, panel B). The
reduced levels were observed in CF-patients even before the
diagnosis of diabetes mellitus even though it was more dis-
tinct in patients with CFRD. This pattern was not observed
for total GLP-1 (Fig. 1, panel A).
A strength of this study is that we have access to a large
number of patients with CF, who also are among the oldest
CF patients in the world [1]. This gives us the exceptional
opportunity to study late stage complications as CFRD. We
choose to use a standardized breakfast instead of glucose
load since we were also interested of the effect mediated by
lipids and proteins. A limitation of the study is that the first
postprandial sample was collected after 15 min. Since the se-
cretion of GLP-1 starts immediately after food intake it
would have been interesting to observe the response in the
early phase between 1 and 10 min after the meal. Degradation
of active GLP-1 is rapid with a half-life of 1–2 min and peaks
before the first 15 min could therefore have been missed.
The pathogenesis of CFRD is unclear. The gene mutations
in CF is well described and do not have any known linkageut diabetes (CF), and patients with cystic fibrosis related diabetes (CFRD). Data
30 min 45 min 60 min
6.2 (4.9–8.7) 5.5 (4.6–8.8) 5.7 (4.6–8.8)
4.0 (3.4–6.6) 4.0 (2.3–5.3) 3.7 (2.3–4.6)
3.1 (1.3–5.6) 2.5 (1.7–4.5) 2.6 (1.3–4.9)
Fig. 2. The lines show the median C-peptide levels at different points of time
after ingestion of the meal. Patients with Cystic fibrosis related diabetes,
CFRD (♦, n=19) had significantly lower levels of C-peptide compared to
non diabetic subjects with CF (∎, n=29) and healthy controls (⃝ , n=18). No
significant difference was observed between healthy controls and CF patients
without diabetes.
Table 3
Total GLP-1 concentrations (pmol/L) in levels in controls, patients with cystic fibrosis without diabetes (CF), and patients with cystic fibrosis related diabetes
(CFRD). Data are presented as median levels followed by interquartile range (IQR).
O min 15 min 30 min 45 min 60 min
Controls (n=18) 12.7 (8.0–17.1) 16.6 (9.4–21.9) 17.9 (11.1–23.4) 15.6 (8.0–24.0) 17.4 (13.0–24.1)
CF (n=29) 11.4 (5.6–19.6) 16.7 (10.2–28.4) 15.7 (11.2–27.3) 14.6 (9.1–20.3) 11.8 (8.6–22.8)
CFRD (n=19) 9.4 (7.6–22.2) 16.4 (10.4–34.4) 12.9 (8.7–31.5) 15.7 (8.7–31.5) 16.1 (7.1–34.7)
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HLA-haplotypes [26]. We have also tested all patients for
GAD-antibodies since these are frequently found in patients
with T1D. We only found one patient positive for GAD-
antibodies, which could be either due to a coexistence of
T1D and CF in this specific patient or simply represent the
background positivity of GAD-antibodies in the general popu-
lation [27]. The argument against T1D in this patient is that the
C-peptide level reflected a good endogenous insulin produc-
tion. Since no other parameter distinguished the patient from
the other CFRD it was decided to not exclude the patient
from further analysis. Patients with CF and IGT were also
interesting to study and therefore not excluded in this study.
These patients were referred to the non-diabetic group and
we did not achieve any differences in the results by excluding
these subjects.
The low levels of active GLP-1 found in our CF patients
could be due to either decreased secretion from L-cells or
more rapid degradation by DPP-IV. One interesting observa-
tion was that even fasting levels of active GLP-1 were lower
in CF patients in agreement with another recent study [28].
This study also suggested an impaired secretion of both GLP-
1 and GIP in patients with CF after a meal rich in both carbo-
hydrates and lipids. The secretion of GLP-1 was normalized
after pancreatic enzyme supplementation and the increase in
GLP-1 was parallel with a decrease in gastric emptying in
that study. In contrast, we were not able to see effects of
pancreatic enzyme supplementation on GLP-1 in our study.
Reports on gastric emptying rate in CF are also conflicting
and both increased and delayed gastric emptying have been
suggested in this group of patients [28-32]. Together with
gastric dysmobility and malnutrition often observed in these
patients it is tempting to speculate on the impact of incretins
in this group of patients. Could GLP-1 agonist treatment that
is frequently used in T2D be beneficial in CFRD? GLP-1 ago-
nists have the additive effects of delaying gastric emptying,
decreased appetite and decreased glucagon secretion. These
effects are desirable in T2D but not in patients with CFRD.
The positive effect is therefore not transferrable to this patient
group. However, the potential with incretin drugs given to
CF patients is worth to be further explored.
The decreased levels of active but not total GLP-1 in our CF
patients could also indicate a higher rate of degradation, that is
an increased DPP-IV activity. The expression of DPP-IV is
widely occurring also outside the intestinal tract since it has
been demonstrated to be expressed in human lung, liver, spleen,
thymus and prostate tissue [33]. It has also been suggested to
be a costimulator of lymphocyte activation [34]. Several
hormones, cytokines and chemokines are believed to beprocessed by this serine peptidase [35-37] which makes the
enzyme an important regulator of the immune system. The
transcription of DPP-IV is controlled by gamma activated
sites (GAS elements) [38], making interferons vital initiators
[39]. Other proinflammatory cytokines such as tumor necrosis
factor (TNFα), IL-2 and IL-12 has been suggested to affect
translation and translocation of DPP-IV to the cell surface
[40,41]. Thus, an increased DPP-IV activity would have sever-
al physiological effects besides degradation of glucagon and
incretins.
The early onset of chronic inflammation in the CF patients is
mainly mediated by neutrophils and even platelets have been
suggested [42]. Proinflammatory molecules of the innate im-
mune system such as IL-1, IL-6 and IL-8 are elevated in CF,
all of which could be regulated by serine peptidases. Whether
DPP-IV or other related serine peptidases have increased
enzymatic activity or not in patients with CF cannot be con-
cluded by this study and needs to be further investigated.
Impaired insulin secretion is common in CF patients with
exocrine pancreatic insufficiency [43] but the role of insulin
resistance in the development of CFRD is inconsistently
Table 4
C-peptide concentrations (nmol/L) in controls, patients with cystic fibrosis without diabetes (CF), and patients with cystic fibrosis related diabetes (CFRD). Data are
presented as median levels followed by interquartile range (IQR).
O min 15 min 30 min 45 min 60 min
Controls (n=18) 0.45 (0.32–0.63) 1.03 (0.71–1.47) 1.09 (0.97–1.75) 1.20 (0.86–1.26) 1.07 (0.78–1.25)
CF (n=29) 0.40 (0.30–0.58) 0.93 (0.58–1.20) 1.33 (1.05–1.61) 1.40 (1.10–1.60) 1.32 (1.1–31.83)
CFRD (n=19) 0.25 (0.19–0.47) 0.35 (0.24–0.47) 0.45 (0.25–0.81) 0.56 (0.30–0.77) 0.56 (0.36–1.00)
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icantly lower in patients with CFRD compared to in healthy
controls but also compared to in patients with CF without dia-
betes. Most of non-diabetic patients with CF have some degree
of pancreas insufficiency, however the C-peptide levels did
not differ from healthy control subjects (Fig. 2, Table 4). The
insulin peak is normally delayed after meal or glucose load
in patients with CF [46] compared to in healthy subjects [47]
where the C-peptide peak has been reported to appear within
6 min after stimulation [48]. We were not able to observe
any early delay in C-peptide peak in our patients since we
had the first postprandial sample after 15 min.
Postprandial responses of regulatory enteral peptides have
been studied before but the results have been sometimes con-
flicting [46,47,49,50]. Reduced levels of gastric inhibitory pep-
tide (GIP) after stimulation with milk or standard test meal have
been reported [46,49] but no change was observed after stimu-
lation with glucose only [47]. Conflicting results of postprandi-
al responses may be due to the content of the meal. This could
therefore explain why we found decreased levels of active
GLP-1 in patients with CF when stimulating with a standard
test meal (carbohydrates, proteins and lipids) while Lanng and
colleagues found active GLP-1 to be unaffected when stimulat-
ing with oral glucose [47].
The low level of active GLP-1 in response to meal that was
demonstrated in all patients with CF, regardless of the presence
of diabetes, could on the other hand indicate an early distur-
bance of food-induced stimulation of GLP-1 in these patients.
The disappearance of the peak of active GLP-1 precedes
the decrease in insulin secretion, since low levels of active
GLP-1 were seen in all patients with CF but with simultaneous
low levels of C-peptide only in these with manifest diabetes.
Insulin secretion must therefore be maintained by other stimuli
than GLP-1 as for example by small imperceptible elevations
in glucose concentration before diabetes is diagnosed. The
failure of GLP-1 peaking could also explain previous findings
of a delayed insulin peak after enteral stimulation in patients
with CF [46].
In conclusion, bioactive GLP-1 in patients with CFRD and
CF was found to be reduced compared to in healthy controls
after meal stimulation. Low levels of active GLP-1 preceded
the decrease in endogenous insulin secretion in CF patients,
since low GLP-1 levels and normal C-peptides were observed
in CF patients not yet diagnosed with diabetes. These findings
supported the hypothesis that the disturbance of active GLP-1
could be closely connected to the primary cause of CFRD.
With regard to new therapeutic agents in the treatment of
diabetes in form of GLP-1 agonists and DPP-IV inhibitors
these results are important. The possibility to treat CFRDwith these new drugs is worth to investigate and calls for new
clinical trials.
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